Proteins IL-11 , Human
- Known as:
- Proteins Interleukin-11 , Human
- Catalog number:
- C006
- Product Quantity:
- 10μg
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Proteins IL-11 Human
Related genes to: Proteins IL-11 , Human
- Gene:
- IL11 NIH gene
- Name:
- interleukin 11
- Previous symbol:
- -
- Synonyms:
- IL-11, AGIF
- Chromosome:
- 19q13.42
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-06
- Date modifiied:
- 2016-10-11
Related products to: Proteins IL-11 , Human
Related articles to: Proteins IL-11 , Human
- Graves' orbitopathy (GO), a complex autoimmune disorder, remains the most common extrathyroidal manifestation of Graves' disease. Its pathogenesis is characterized by a progressive transition from inflammation to fibrosis, leading to debilitating ocular complications. While high-dose intravenous glucocorticoids have been the standard treatment for active moderate-to-severe GO, their lack of specificity to GO pathogenesis and limited efficacy in the fibrotic phase underscore the need for targeted therapies. This review explores emerging therapeutic targets in GO, focusing on pathways implicated in both inflammatory and fibrotic mechanisms. Teprotumumab, an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, has revolutionized GO treatment, demonstrating clinical efficacy in reducing proptosis and inflammation. Interleukin-6 (IL-6) inhibitors including satralizumab are undergoing clinical trials. New studies on molecular pathways have been conducted regarding inflammation and fibrosis of GO, including platelet-derived growth factor/fibroblast growth factor signaling, yes-associated protein 1/transcriptional coactivator with PDZ-binding motif mechanotransduction, sphingosine-1-phosphate (S1P)/S1P receptor axis, bone morphogenic protein 7, IL-11, IL-17 and microRNAs as well as, IGF-1R/thyroid-stimulating hormone receptor crosstalk, and IL-6 trans-signaling. Most studies focus on exploring the potential of therapeutic agents through preclinical investigations but represent promising therapeutic avenues. Therapies targeting these pathways may offer a promising potential efficacy across the entire disease spectrum, from inflammation to fibrosis, thus overcome the limitations of conventional glucocorticoid therapy and expand therapeutic options in GO. Advances in GO models may bring forward a new era of GO treatment. - Source: PubMed
Publication date: 2025/08/14
Kang Young JaeYoon Jin Sook - This study aims to elucidate the role of Enterococcusin the progression from inflammatory bowel disease to colorectal cancer (CRC), with a focus on identifying key metabolites and host genes regulated by Enterococcusand their influence on CRC development. - Source: PubMed
Publication date: 2026/03/30
Huang GangLiu JianiCheng ZhipengChen YixinChen KexinLiu WanLiu HancongXia XinhaoLu ManCui WenxiZhang QingqingYuan YiZhong FeiLiao Yiwen - Elevated levels of platelet-derived growth factor (PDGF) isoforms in fibrosis are implicated in driving a dysfunctional profibrotic fibroblast phenotype. This study investigated the differential effects of the five PDGF isoforms (AA, AB, BB, CC, and DD) in inducing neonatal dermal and fetal lung fibroblast contraction, proliferation, cytokine production, myofibroblast differentiation, and extracellular matrix (ECM) deposition. All PDGF isoforms, except PDGF-AA, increased contraction of 3-dimensional collagen I gels by dermal ( < 0.01) and lung fibroblasts ( < 0.05) compared to media control. PDGF-AB, BB, and CC enhanced proliferation only in dermal fibroblasts ( < 0.05). PDGF-BB induced profibrotic IL-11 cytokine release in dermal and lung fibroblasts ( < 0.0001) and IL-6 cytokine release in dermal fibroblasts ( < 0.05) compared to media control. None of the PDGF isoforms affected ECM synthesis or myofibroblast differentiation. Dermal fibroblasts exhibited elevated PDGF Receptor-β (PDGFRβ) expression ( < 0.01) and increased basal ERK1/2 phosphorylation ( < 0.05) compared to lung fibroblasts. In summary, PDGF modulates fibroblast functions in a tissue-specific manner, with PDGF-BB driving profibrotic processes in dermal fibroblasts through high PDGFRβ expression and ERK1/2 signalling. Further research is needed to explore the benefit of tissue and isoform-specific PDGF inhibition strategies in skin and lung fibrosis. - Source: PubMed
Publication date: 2026/04/01
Kohlen BrandonBadyal RaveenKeen Kevin JDunne James VHackett Tillie-Louise - Interleukin-11 (IL-11), a pleiotropic cytokine belonging to the interleukin-6 (IL-6) family, is implicated in the initiation and progression of various malignancies. Recent studies revealed that IL-11 plays multifaceted roles in prostate cancer, contributing to tumor cell proliferation, castration resistance, bone metastasis, and chemotherapeutic resistance. Interleukin-11 has emerged as a promising target for both diagnostic and therapeutic strategies. This review outlines the molecular structure and biological functions of IL-11; summarizes its role in early diagnosis, prognostic evaluation, tumor progression, and therapeutic intervention for prostate cancer; and explores its potential as a novel therapeutic target. - Source: PubMed
Publication date: 2026/01/29
Zhong JinghuaDuan XiaoluWei ZiyiZhu WeiZhao ZhijianZeng Guohua - The genus is widely used for several purposes, including wound healing and the treatment of prostate cancer. In this context, we investigated one member, namely, extracts for antioxidant, enzyme inhibition, inflammation, oxidative stress and matrix degradation in lipopolysaccharide (LPS)-induced human dermal fibroblasts (LPS + HDF). The extracts were also characterized by ultra-performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC-QToF). In general, the methanol extract contained the highest phenolic (145.38 mg gallic acid equivalent (GAE) g) and flavonoid (34.82 mg rutin equivalent (RE) g) content and exhibited the best antioxidant properties (2,2-diphenyl-1-picrylhydrazyl (DPPH):494.40 mg trolox equivalent (TE) g; cupric reducing antioxidant power (CUPRAC): 881.03 mg TE g; phosphomolybdenum assay: 3.48 mmol TE g) compared to the ethyl acetate and water extracts. The methanol and ethyl acetate extracts exhibited more substantial enzyme-inhibitory effects than the water extracts. Oenothein B, pedunculagin, galloyl glucose and ellagic acid were the predominant compounds based on the chemical profile. The Water-Soluble Tetrazolium 1 (WST-1) assay confirmed cell viability; protein synthesis of nuclear factor-kappa B (NF-κB) and activator protein-1 (AP-1) transcription factors, and of interleukin-6 (IL-6), interleukin-11 (IL-11), and interferon gamma (IFN-γ), was determined by western blot. Matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) activities, which are involved in extracellular matrix (ECM) homeostasis, were measured by gelatin zymography, and gene expression levels were measured. Cellular oxidative stress was assessed using the diacetyldichlorofluorescein (DCFDA) assay. The results suggest that extracts may be considered potential phytotherapeutic agents to promote dermal healing with their multi-targeted anti-inflammatory and antioxidant properties. - Source: PubMed
Publication date: 2026/04/08
Kurt-Celep InciCusumano GaiaFlores Giancarlo AngelesPeron GregorioSenkardes IsmailAngelini PaolaEmiliani CarlaUba Abdullahi IbrahimZengin Gokhan